Dedicated to pharmaceuticals since its foundation, Chong Kun Dang has overcome many challenges,while continuing to grow and contribute to the advancement of Korea’s pharmaceutical industry.
In the days when Korea imported 100% of the raw materials required for medicines from abroad, we built Korea’s largest plants for chemical synthesis and fermentation, making it possible to produce pharmaceutical ingredients locally using our own technology. From there, we had driven Korean Pharmaceutical Industry with this breakthrough on the path toward modernization.
Furthermore, we became the first Korean pharmaceutical company to export products to the US market through the obtainment of the U.S. FDA
approval. Now, on its 77th anniversary, we promise to put all efforts to lead continuous change and innovation, positioning Chong Kun Dang as a global pharmaceutical company with a competitive edge in the international market.
|Foundation||May 7, 1941 (Spin off on : November 5, 2013)|
|Business Line||Manufacturing, Sales and Marketing of Medicine|
|Paid in Capital||23,5 Bil. (Won)|
|Head Office||8, Chungjeong-ro, Seodaemun-gu, Seoul, Korea|
|TEL/FAX||82-2-2194-0300 / 82-2-2194-0369|
Chong Kun Dang Pharmaceutical Corp. is one of leading Korean pharmaceutical manufacturers and has a great strength on domestic sales not only with prescription drugs indicated for anti-hypertension, anti-hyperlipidemia and anti-diabetics but also with OTC drugs such as Penzal, Prefemine, Modcol and consumer health such as insecticides, hairdye, etc.
Chong Kun Dang has a complete
portfolio of prescription
pharmaceutical products for the
entire segment and therapeutic classes, supported not only by
own-developed NCE drugs Camptobell as a anticancer and
anti-diabetic, Duvie, but also
Lipilou, and immunosuppressant Tacrbell
Chong Kun Dang’s OTC drugs consist of
products known for their therapeutic benefits, as well as
supplements and other preventive products.
Penzal which is best- seller for headache in Korea, Zelcom as No.1 antithelmintic,
and fast-effective digestive Sok-chung drink carry strong brand names that have dominated the market over the
past few decades.
In recent days, some of Chong Kun Dang’s preventive OTCs are positioning to advance women’s health such as Prefemine for premenstrual syndrome and Simidona for menopause symptom, Bolgre for iron supplements.
Chong Kun Dang provides high-
quality healthcare supplements with preventive benefits including
prebiotics complex Prelacto and Premium Omega-3+vitamin series
caring for modern people in their busy life.
Chong Kun Dang’s selection of
healthy beverage products range from
Sok-chung cool, and Ja- Whang,
San-e-nun-Sam with red-ginseng
based healthy drink
to insecticides Jjong aerosol.
Chong Kun Dang is expanding the market in worldwide with strategic products in immunosuppressants, anti-cancers and antibiotics. In order to
grow strength in Glocalization (Globalization + Localization), Chong Kun Dang opened representative office in Vietnam since 2012 and established
Joint Venture company in Indonesia
Chong Kun Dang’s manufacturing site in CheonAn city supply quality prescribed products meeting with global standard into worldwide as Japan, China, South-east Asian, MENA and African countries. In recent, it is being strengthen to dominant market share in ASEAN region through Indonesian JV company, VN rep. office and further footholds.
In September 2015, Chong Kun Dang has established the joint venture company PT CKD
OTTO Pharmaceuticals with PT OTTO Pharmaceutical Ltd. which is one of leading local
pharmaceutical companies in Indonesia. In the future, PT CKD OTTO as a production base
not only for domestic market, but only for near Asian, MENA and EU countries, will
manufacture and distribute anti-cancer drugs such as Belloxa, Gemtan, etc. through which Chong Kun Dang has global competitiveness.
Since Chong Kun Dang’s Vietnam representative office has been established in 2012, it has been raised company awareness in domestic by expanding the pipeline of prescription drugs as well as health care products. Through various promotion activity, oncology products (Belloxa, Gemtan), anti-hypertensives (Candemore plus), antibiotics (Kmoxilin) and various health care products including red-ginseng liquid, collagen capsule, probiotics, etc are being distributed in nationwide.
Chong Kun Dang is focused on in-licensing novel drugs which offers better solution for chronic disorders such as diabetes and cardiovascular diseases, as well as for anti-cancer therapies and neurological diseases with high medical unmet needs. Having developed Duvie®, the new drug for type II diabetes, Chong Kun Dang is actively expanding its global presence with the best-in-class anti-cancer pipelines (CKD-516 and CKD-581) and dyslipidemia therapy, starting from the neighboring Asian markets. Further, Chong Kun Dang has an in-house technology platform for HDAC6-selective inhibitors which provides the novel mechanism of action.We are enthusiastically preparing for the global market entry via strategic business diversification, specificallytargeting auto-immune diseases, neurological disorders, and cancer.
Supported by its long presence in Korean pharmaceutical industry and strong sales and marketing capacity, Chong Kun Dang is involved in numerous business alliance relationships with the most prestigious multinational companies in various fields. Over the last decade, Chong Kun Dang has formed the partnership with MNCs such as Bayer, Roche, Allergan, Pfizer, and MSD and Amgen and, as a result, Chong Kun Dang has an unrivaled leadership in the local market enhanced by its robust product portfolio which now covers a broad range of therapeutic classes with innovative, outstanding drugs. Chong Kun Dang will continue to work towards mutual development through global business partnering.
|Affiliated Companies||Bayer, B.Braun, Cheplapharm, Riemser|
Avelox®, Ciprobay®, Ciprouro®, Hospital Solns,
Nutriflex®, Lipidem®, Xenical®, Dilatrend®, Anexate®,
|Affiliated Companies||Roche, Zeller, Ferring|
Rivotril, Valcyte, Minirin
|Affiliated Companies||Eli Lilly, Alvogen, Cara, S1 Biopharma, Allergan, MSD, Pfizer, Amgen|
CKD-943(CR-845),Lorexys Restasis®,Januvia family®,
Mitsubishi Tanabe, Ayumi, Asahi Kasei,
Depas®, Rimatil®, Bredinin®, Elcitonin®,
|Affiliated Companies||Expascience, Vivacy, Neovacs|
|Product Names||Imotun®, Stylage®, CKD-971 (IFN-alpha kinoid)|
|Affiliated Companies||Menarini, Italfarmaco|
|Product Names||Neuropacid®, Gilatilin®|
|Affiliated Companies||Valeant, Cardiome|
|Product Names||Colazal®, Brinavess®|
|Affiliated Companies||GC Aesthetics|
|Affiliated Companies||Sun Pharma|
|Country||Affiliated Companies||Product Names|
|GERMANY||Bayer, B.Braun, Cheplapharm, Riemser||
Avelox®, Ciprobay®, Ciprouro®, Hospital Solns, Nutriflex®, Lipidem®,
Xenical®, Dilatrend®, Anexate®, Ismo®
|SWITZERLAND||Roche, Zeller, Ferring||Tamiflu®, Prefemin®, Cimidona®, Rivotril, Valcyte, Minirin|
|USA||Eli Lilly, Alvogen, Cara, S1 Biopharma, Allergan, MSD, Pfizer, Amgen||
CKD-943(CR-845),Lorexys Restasis®,Januvia family®,
|JAPAN||Mitsubishi Tanabe, Ayumi, Asahi Kasei, ReqMed||Depas®, CKD Rimatil®, Bredinin®, Elcitonin®, Penpol®|
|FRANCE||Expanscience, Vivacy, Neovacs||Imotun®, Stylage®,CKD-971 (IFN-alpha kinoid)|
|ITALY||Menarini, Italfarmaco||Neuropacid®, CKD Gliatilin®|
|CANADA||Valeant, Cardiome||Colazal®, Brinavess®|
Cheon-An plant established aspects of global pharmaceutical production facility through completion of separated cephalosporin and penicillin
plants with level of cGMP in 2013, and certified the GMP (Good manufacturing practice) compliance through inspections of several domestic and
foreign regulatory authorities.
Also, the plant has maximized the operating efficiency successively starting with establishment of SAP ERP (Enterprise Resource Planning) in 2010, QMS (Quality Management System) and LIMS (Laboratory Information System) for efficient substantial manufacturing control and quality assurance.
Cheon-An plant with high-tech production facility, excellent manufacturing and testing equipment and optimized manufacturing environment is steadily evolving today through continued securing of human resources and facility investment, and plays a pivotal role as a production base to realize value and vision of global Chong Kun Dang Pharmaceutical Corp.
The warehouse establishes unmanned transport system for entire logistical flows such as material dispensing, manufacturing, packaging and warehousing of finished products by using LGV and RGV, and supplies the medicinal product to hospitals, pharmacies, general practitioners and so on through digital picking system.
Quality control team determines conformity of raw materials, packaging materials and
finished products to established specifications after testing, and controls the quality
so that customer take safe medicinal products.
The laboratory conducts accurate test and contributes to GMP compliance and development based on quality talent and advanced analysis equipment.
The process from materials to manufacture finished product is controlled in compliance with GMP through advanced automation equipment and verified process control.
Since the foundation, Chong Kun Dang has been pursuing a disease-free society
by developing excellent medicines.Cognizant of the importance of drug discovery, Chong Kun Dang was the first in Korea to run its own research institute it also invested a huge portion of its resources in nurturing and training research manpower.
Chong Kun Dang Research Institute is characterized by three independent laboratories: The New Drug Discovery Labs, for identifying innovative drug candidates, The Technology Development Labs, dedicated to generic drugs,
APIs, and botanical drugs, and the Bio Research Labs for developing antibodies, vaccines, and recombinant proteins.
Chong Kun Dang was able to stand as one of the top local pharmaceutical companies with distinguished achievements in drug development including the following.
Focus on medical